VivoSeq
Oncology

Lung Cancer

575

Pipeline Programs↗

216

Active Trials↗

156

Companies Involved↗

Lung Cancer is a highly competitive landscape with 575 programs across 156 companies. The most active players are Chongqing Precision Biotech Co., Ltd, Synta Pharmaceuticals Corp., BioNTech US Inc.. 60 therapies are approved with 104 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

98/100

Pipeline Velocity

65/100

Mech. Concentration

5/100

Completion Rate

72/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Chongqing Precision Biotech Co., Ltd

1 program

Phase 1S

Synta Pharmaceuticals Corp.

1 program

Phase 1B

BioNTech US Inc.

1 program

Phase 1N

Northwest Biotherapeutics

1 program

Phase 1S

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

1 program

Phase 1B

BioNumerik Pharmaceuticals, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical45

Cemiplimab

Regeneron

Dacomitinib

Pfizer

Nefopam

Yonsei University

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Atezolizumab

Roche

Phase 191

Sargramostim

Sanofi

Abemaciclib

Eli Lilly

Sarilumab

Azienda U.S.L. 1 di Massa e Carrara

Porfimer Sodium

Pinnacle Biologics Inc.

Ganetespib

Synta Pharmaceuticals Corp.

Phase 2275

Aldesleukin

Iovance Biotherapeutics, Inc.

Tipifarnib

Kura Oncology, Inc.

Crizotinib

Prism Pharmaceuticals

Antineoplaston A10

Burzynski Research Institute

Serplulimab

Shanghai Henlius Biotech

Phase 3104

Pemetrexed Disodium

Gynecologic Oncology Group

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Vinorelbine Tartrate

Gynecologic Oncology Group

Canakinumab

Novartis

Isotretinoin

Conrado Roberto Hoffmann Filho

Approved60

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Vinblastine

Eli Lilly

Valacyclovir

Glaxo Dba Glaxosmithkline

Docetaxel

Avyxa

Amifostine

Legacy Health System

Analysis

Modality Breakdown

84%

Small molecule

529 of 632 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody599%Vaccine183%Protein / enzyme112%Cell therapy102%Antibody–drug conjugate2<1%Peptide2<1%Other1<1%

Small molecule leads; the ring shows all 632 classified programs, each share of the total. Modality classified for 100% of 687 pipeline programs.

Analysis

Trial Status

790

clinical trials

Completed307 · 39%
Unknown status144 · 18%
Recruiting117 · 15%
Terminated89 · 11%
Active, not recruiting62 · 8%
Not yet recruiting35 · 4%
Other36 · 5%

Clinical Trials

Trial Activity

790 trials

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT05963867·12 enrolled
Supplementation of n-3 PUFA in the Modulation of Lean Mass in Patients With Lung Cancer Receiving a High-protein Diet
Recruiting·UUniversidade Federal do Rio de Janeiro·N/A·NCT04965129·50 enrolled
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
Recruiting·CCanadian Cancer Trials Group·Phase 2/3·NCT04093167·230 enrolled
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT05620342·24 enrolled
Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors.
Recruiting·—·Phase 1·NCT06928922·83 enrolled
A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer
Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06768151·48 enrolled
Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer
Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06992583·60 enrolled
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
Recruiting·HHC Biopharma Inc.·Phase 1·NCT07381829·328 enrolled
Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
Recruiting·PPeking University First Hospital·N/A·NCT04209218·1,988 enrolled
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04789681·50 enrolled
Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy
Recruiting·—·Phase 2·NCT06667154·33 enrolled
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Recruiting·HHunan Province Tumor Hospital·Phase 3·NCT05055908·12,000 enrolled
Joint Thoracic Oncology Research Unit of LYon: Lung cancerS DatabaSE (ULYSSE)
Recruiting·HHospices Civils de Lyon·N/A·NCT05267041·4,000 enrolled
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04410796·571 enrolled
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Recruiting·—·Phase 1·NCT05483491·30 enrolled
Page 1 of 53

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)